Estrogen Receptor Agonist Market Forecast Report 2023-2035

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Estrogen Receptor Agonist Market size is poised to surpass USD 9 Billion by 2035, observing nearly 7% CAGR from 2023 to 2035. In the year 2022, the industry size of estrogen receptor agonist was USD 4 Billion. This rise in market demand is anticipated to be driven by the growing prevalence of cardiovascular disease. According to the World Health Organization, with about 17.9 million deaths per year, cardiovascular diseases (CVDs) are the major cause of death globally. Hence, in order to treat this the demand for different treatments is growing among which estrogen receptor agonist is most preferred. Additionally, it has been proven to be one of the safer treatments for cardiovascular diseases.

Furthermore, women who are in their post-menopausal period are usually given estrogen receptor agonist treatment since they suffer various consequences such as a decline in the concentration of sex steroid hormones in the blood owing to a decline of ovary function. By 2030, the post-menopausal women are projected to reach 1.2 billion, globally.

Get more information on this report: Request Free Sample PDF

Estrogen Receptor Agonist Market: Key Insights

Base Year	2022
Forecast Year	2023-2035
CAGR	~ 7%
Base Year Market Size (2022)	~ USD 4 Billion
Forecast Year Market Size (2035)	~ USD 9 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Global Estrogen Receptor Agonist Market: Growth Drivers and Challenges

Growth Drivers

Growing Prevalence of Osteoporosis 18.3% of people worldwide were estimated to have osteoporosis in 2021. Hence, in order to treat osteoporosis, the demand is on a surge for estrogen receptor agonists. Raloxifene is the most common type of estrogen which is approved by FDA used for this treatment.
Rise in Women Suffering from PCOS Between 4% and 20% of women worldwide were believed to have PCOS in 2022. Further, PCOS have a huge adverse effect on female leading to irregular period and acne. Hence, polycystic ovary syndrome treatment on timely basis is necessary. Therefore, in order to control menstrual cycles in PCOS patients, oral contraceptives (OCs; with combined estrogen and progestin) are the most widely used form of medication.
Surge in the Application of Estrogen in Asthma There has been growing research on the use of estrogen receptor agonist in the treatment of asthma. Beyond the reproductive system, estrogen plays a variety of tasks in both males and females, including controlling inflammation, intracellular calcium levels, and cell proliferation and differentiation. One of the characteristics of asthma is the infiltration of inflammatory cells such as lymphocytes, monocytes/macrophages, neutrophils, and eosinophils into the airways, particularly eosinophilic infiltration. Hence, it is poised that the estrogen receptor agonist would be used. Hence, further, the investment in research activities on this topic is anticipated to rise in order to prove the conclusion.

Challenges

High Cost of Treatment
Lack of Processionals who are Skilled in this Field – The use of estrogen receptor agonists is a new form of treatment on which still research is going on for its use to treat different diseases. Hence, not a large number of people are aware of this treatment. Also, since it is not popular enough there is a lack of professionals, especially in rural regions. Hence, this factor is projected to hinder the estrogen receptor agonist market growth.
Adverse Effect of Estrogen Receptor Agonist

Estrogen Receptor Against Segmentation

Route of Administration (Oral, Parental)

Estrogen receptor agonist market from the oral segment is anticipated to garner the highest revenue by the end of 2035. This segment growth is estimated to boost on account of its cost efficiency. Since parenteral drugs must be sterile and isotonic, the oral pharmaceuticals on the market are less expensive, which results in financial savings for the patient. Moreover, oral medication gets absorbed at a faster rate. Hence, they are most preferred.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)

The hospital pharmacies segment in the estrogen receptor agonist market is set to have noteworthy growth over the forecast period. Most of estrogen receptor agonist drugs are prescribed by the doctors. Hence, the pharmacies attached to the hospitals are estimated to satisfy the growing demand for this medication.

Our in-depth analysis of the Estrogen Receptor Agonist Market includes the following segments:

Product Type	Endogenous Synthetic Natural
Indication Type	Cancer Neurodegenerative Diseases Inflammatory Diseases Cardiovascular Diseases
Route of Administration	Oral Parental
Distribution Channel	Hospital Pharmacies Retail Pharmacies Drug Stores Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Estrogen Receptor Agonist Industry Regional Synopsis

APAC Market Statistics

The Asia Pacific estrogen receptor agonist market is set to have the highest growth by the end of 2035, backed by the growing geriatric population in this region. In Asia and the Pacific region, one in four persons is expected to be older than 60 by 2050. Moreover, this transition is expected to happen relatively quickly in several nations, such as the People's Republic of China, Sri Lanka, Thailand, and Viet Nam. Hence, the demand for estrogen receptor agonist is poised to grow. Old people are prone to various diseases such as cardiovascular disease, asthma, and more. Hence, in order to treat or prevent the growth of disease, the market is estimated to grow.

North American Market Forecast

The North America estrogen receptor agonist market is projected to have significant growth over the forecast period. The market in this region is poised to grow on account of rising cases of cancer.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the estrogen receptor agonist market?

Ans: The major factors driving the growth of the market are the growing prevalence of osteoporosis, the rise in women suffering from PCOS, and the surge in the application of estrogen in asthma.

2) What would be the CAGR of the estrogen receptor agonist market over the forecast period?

Ans: The market size of estrogen receptor agonist is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023 â€“ 2035.

3) Who are the major players dominating the estrogen receptor agonist market?

Ans: The major players in the market are AstraZeneca, Eli Lilly and Company, ESTRIGENIX, Karo Healthcare AB, and more.

4) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

5) What are the segments in the estrogen receptor agonist market?

Ans: The market is segmented by product type, indication type, route of administration, distribution channel and by region.

6) Which segment captures the largest market size in the route of administration segment in the estrogen receptor agonist market?

Ans: The oral segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

7) What are the challenges affecting the market growth?

Ans: High cost of treatment, lack of professions who are skilled in this field, and adverse effect of estrogen receptor agonist are estimated to be the growth hindering factors for the market expansion.

8) Which region will provide more business opportunities for the growth of the estrogen receptor agonist market in the future?

Ans: The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.